Drug Approval | June 10, 2022
Sanofi Dupixent gets USFDA nod for atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Dupixent peak sales ambition raised to more than €13 billion
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Subscribe To Our Newsletter & Stay Updated
